Nurix CSO exercises RSUs, sells shares for taxes
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported compensation-related stock activity involving vested restricted stock units and a small mandated share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported compensation-related stock activity involving vested restricted stock units and a small mandated share sale. On April 30, 2026, she exercised RSUs into a total of 8,608 shares of common stock.
On the same date, she sold 3,214 shares of common stock at a weighted average price of $16.6453 per share solely to cover tax withholding obligations under Nurix’s equity incentive plans. These “sell to cover” transactions were not discretionary trades. After these transactions, she held 120,399 common shares directly.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Hansen Gwenn
Role
Chief Scientific Officer
Sold
3,214 shs ($53K)
Approx. gross sale proceeds
$53K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 2,000 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 3,750 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 2,858 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,750 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,858 | $0.00 | $0.00 |
| Sale | Common Stock | 3,214 | $16.6453 | $53K |
Holdings After Transaction:
Restricted Stock Units — 37,867 contracts (Direct);
Common Stock — 120,399 shares (Direct)
Footnotes (7)
- F1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- F3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F4. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F5. RSUs do not expire; they either vest or are canceled prior to the vest date.
- F6. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F7. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Key Figures
Shares sold for taxes: 3,214 shares
Weighted average sale price: $16.6453 per share
Shares from RSU vesting/conversion: 8,608 shares
+4 more
7 metrics
Shares sold for taxes
3,214 shares
Common stock sold on April 30, 2026 to cover tax withholding
Weighted average sale price
$16.6453 per share
Tax-related sale of 3,214 shares; price range $16.51–$16.78
Shares from RSU vesting/conversion
8,608 shares
Common stock acquired via RSU exercises on April 30, 2026
Post-transaction holdings
120,399 shares
Common stock directly held after April 30, 2026 transactions
RSU tranche 1 vesting pattern
1/12 quarterly over 3 years
First quarterly vesting on July 30, 2023, subject to continued service
RSU tranche 2 vesting pattern
1/12 quarterly over 3 years
First quarterly vesting on July 30, 2024, subject to continued service
RSU tranche 3 vesting pattern
1/12 quarterly over 3 years
First quarterly vesting on July 30, 2025, subject to continued service
Key Terms
restricted stock units ("RSUs"), sell to cover, equity incentive plans, tax withholding obligations, +1 more
5 terms
restricted stock units ("RSUs") financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
sell to cover financial
"tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
equity incentive plans financial
"mandated by the Issuer's election under its equity incentive plans"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
tax withholding obligations financial
"shares required to be sold ... to cover tax withholding obligations in connection with the vesting"
weighted average sale price financial
"Represents the weighted average sale price. The lowest price at which shares were sold"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Nurix (NRIX) CSO Gwenn Hansen report?
Gwenn Hansen reported RSU vesting and a tax-related share sale. She converted restricted stock units into 8,608 common shares and sold 3,214 shares at a weighted average price of $16.6453 per share to satisfy tax withholding obligations mandated under Nurix’s equity incentive plans.
Was the Nurix (NRIX) insider sale by CSO Gwenn Hansen discretionary?
The sale was not a discretionary trade. Footnotes explain the 3,214-share sale on April 30, 2026 was required to cover tax withholding from RSU vesting, under a mandated “sell to cover” mechanism in Nurix’s equity incentive plans, rather than a voluntary market decision.
How do Nurix (NRIX) restricted stock units (RSUs) vest for CSO Gwenn Hansen?
Her RSUs vest quarterly over three years. Multiple RSU grants vest as to 1/12 of each total award every quarter over three years, with initial vesting dates on July 30 of 2023, 2024, and 2025, contingent on continued service to Nurix at each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
